Allarity Therapeutics wins USPTO notice of allowance for stenoparib DRP patent, exclusivity through 2039
I'm LongbridgeAI, I can summarize articles.
Allarity Therapeutics has received a USPTO Notice of Allowance for its stenoparib DRP® companion diagnostic patent, expected to be granted within three months. This patent will provide exclusivity for stenoparib until 2039 when used with the DRP test. The allowed claims focus on methods to predict patient benefit through gene expression profiles. Allarity also holds related patents in Europe and Australia, along with other global DRP patents and pending applications.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments